Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advancements review observed that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://robertg528jyj3.worldblogged.com/profile